Darmiyan: Testing a Novel Software for Early Detection of Alzheimer’s Disease
Diagnostic Study
Get in touch about this studyWhat is the study about?
The goal of this study is to find out whether Darmiyan is an effective tool for diagnosing Alzheimer’s disease earlier. Darmiyan is a new software that can identify brain changes that may not be visible on traditional MRI brain scans. This project includes two studies to test how accurate and reliable Darmiyan is in predicting and detecting Alzheimer’s disease.
Eligibility – Who can participate?
Participants must:
-
Be able to speak English to complete neuropsychological testing
-
Have a caregiver who can come in and answer questions
-
Be 50 years of age or older
-
Either have no memory complaints, have mild cognitive impairment, or Alzheimer’s disease
Time requirement
-
Study 1 (a prospective study): A baseline visit with follow up at 4 to 9 months
-
Study 2 (a retrospective study): One visit following recruitment through chart review
TDRA study investigator
Dr. Morris Freedman
More information
TDRA Site:
Baycrest
Address: 3560 Bathurst St, North York, ON M6A 2E1
Age Group:
50 - 54, 55 - 59, 65 - 69, 70 - 80, 81 - 85, 86 - 90, 91+
Target Population:
Alzheimer’s disease, Healthy volunteer, Mild cognitive impairment